BCL2 Amplicon Loss and Transcriptional Remodeling Drives ABT-199 Resistance in B Cell Lymphoma Models

Drug-tolerant “persister” tumor cells underlie emergence of drug-resistant clones and contribute to relapse and disease progression. Here we report that resistance to the BCL-2 targeting drug ABT-199 in models of mantle cell lymphoma and double-hit lymphoma evolves from outgrowth of persister clones...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:Cancer Cell
Main Authors: Zhao, Xiaohong, Ren, Yuan, Lawlor, Matthew, Shah, Bijal D., Park, Paul M.C., Lwin, Tint, Wang, Xuefeng, Liu, Kenian, Wang, Michelle, Gao, Jing, Li, Tao, Xu, Mousheng, Silva, Ariosto S., Lee, Kaplan, Zhang, Tinghu, Koomen, John M., Jiang, Huijuan, Sudalagunta, Praneeth R., Meads, Mark B., Cheng, Fengdong, Bi, Chengfeng, Fu, Kai, Fan, Huitao, Dalton, William S., Moscinski, Lynn C., Shain, Kenneth H., Sotomayor, Eduardo M., Wang, Gang Greg, Gray, Nathanael S., Cleveland, John L., Qi, Jun, Tao, Jianguo
Formato: Artigo
Idioma:Inglês
Publicado: 2019
Assuntos:
Article
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC6945775/
https://ncbi.nlm.nih.gov/pubmed/31085176
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.ccell.2019.04.005
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares